Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes.

Alexia Kieffer Matthieu Beuvelet Gerald Moncayo Mersha Chetty Aditya Sardesai Robert Musci Richard D A Hudson

Published in: Infectious diseases and therapy (2024)

This analysis demonstrated that the health and economic burden of RSV would be substantially reduced in all infants experiencing their first RSV season in the UK (including term, preterm, and palivizumab-eligible infants) as a result of a universal immunization strategy with nirsevimab.

Keyphrases

respiratory syncytial virus
respiratory tract
healthcare
public health
gestational age
preterm infants
mental health
low birth weight
preterm birth
type diabetes
health information
risk assessment
adipose tissue
climate change
social media
health promotion